Related Experiment Video
Updated: Mar 23, 2026
The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
Published on: April 16, 2019
The emerging role of FTY720 (Fingolimod) in cancer treatment
Christopher White1, Heba Alshaker2,3, Colin Cooper3
1School of Medicine, Imperial College London, London, UK.
Abstract:
FTY720 (Fingolimod) is a clinically approved immunomodulating therapy for multiple sclerosis that sequesters T-cells to lymph nodes through functional antagonism of sphingosine-1-phosphate 1 receptor. FTY720 also demonstrates a proven efficacy in multiple in vitro and in vivo cancer models, suggesting a potential therapeutic role in cancer patients. A potential anticancer mechanism of FTY720 is through the inhibition of sphingosine kinase 1, a proto-oncogene with in vitro and clinical cancer association. In addition, FTY720's anticancer properties may be attributable to actions on several other molecular targets. This study focuses on reviewing the emerging evidence regarding the anticancer properties and molecular targets of FTY720. While the clinical transition of FTY720 is currently limited by its immune suppression effects, studies aiming at FTY720 delivery and release together with identifying its key synergetic combinations and relevant patient subsets may lead to its rapid introduction into the clinic.
Insights
Fingolimod (FTY720), an MS drug, shows promise as an anticancer therapy by inhibiting sphingosine kinase 1 and other targets. Further research into delivery and combinations could enable its clinical cancer application.
Area of Science:
- Oncology
- Immunology
- Pharmacology
Background:
- Fingolimod (FTY720) is an approved immunomodulator for multiple sclerosis, acting via sphingosine-1-phosphate 1 receptor antagonism.
- FTY720 has demonstrated efficacy in preclinical cancer models, indicating potential therapeutic applications beyond autoimmune diseases.
Purpose of the Study:
- To review emerging evidence on the anticancer properties of FTY720.
- To identify the molecular targets and mechanisms underlying FTY720's anti-cancer effects.
Main Methods:
- Literature review of in vitro and in vivo studies.
- Analysis of FTY720's interactions with molecular targets relevant to cancer.
- Evaluation of FTY720's potential anticancer mechanisms.
Main Results:
- FTY720 inhibits sphingosine kinase 1, a proto-oncogene implicated in cancer.
- FTY720 exhibits anticancer effects through multiple molecular targets.
- Preclinical data support FTY720's potential as an anti-cancer agent.
Conclusions:
- FTY720 possesses demonstrated anticancer properties with potential clinical relevance.
- Targeted delivery, combination therapies, and patient subset identification are crucial for FTY720's clinical cancer application.
- Overcoming immune suppression remains a key challenge for FTY720's transition to cancer therapy.
More Related Videos
06:15Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
04:36Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
Published on: October 17, 2025
Related Concept Videos
02:56Treatment Resistant Cancers
02:56Treatment Resistent Cancers
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:49Cancer Therapies